Vitamin D3 Supplements May Help to Lower HbA1c Levels in Type 2 Diabetes

Oral each day vitamin D3 dosing may increase glycated hemoglobin (HbA1c) ranges around 3- and…

Vitamin D3 Supplements May Help to Lower HbA1c Levels in Type 2 Diabetes

Oral each day vitamin D3 dosing may increase glycated hemoglobin (HbA1c) ranges around 3- and 6-thirty day period intervals in individuals with style 2 diabetic issues mellitus (T2D) going through treatment with metformin, according to authors of a examine revealed in Frontiers in Endocrinology.

In describing the goals of their examine, the investigators observed that patients with T2D generally have quite reduced vitamin D amounts and recent exploration suggests that this deficiency “could enjoy an important purpose in [T2D] pathogenesis via altering several important processes in the advancement of diabetic issues and its complications.” For case in point, they wrote, T2D is characterized by reduced antioxidant capability and greater formation of totally free radicals, and some scientific studies have revealed vitamin D “may have an antioxidant outcome adopted by the inhibition of free of charge radicals generation, consequent lipid peroxidation and oxidative modification of other biomolecules.”

Consequently, they described, “vitamin D supplementation has been proposed as a doable therapeutic tool for [T2D] to enhance [glycemic] command and to avoid the event of complications.” To day, on the other hand, no study has identified the long-time period effect of vitamin D supplementation on persons with T2D, and investigate is lacking on use of vitamin D supplementation in people obtaining regular treatment for T2D (metformin), so investigators of the current analyze sought to elucidate this partnership.

Keep on Looking through

This future, randomized controlled open up-label analyze was performed at a one center in Montenegro, Serbia. Among February 4, 2018 and December 15, 2018, investigators enrolled consecutive clients with T2D on metformin therapy with fantastic metabolic regulate. The most important outcome was the improve in insulin resistance and glycemic command calculated via the homeostasis design of assessments (HOMA-IR) and glycemic parameters these as fasting blood glucose (FBG) and HbA1c.

Secondary outcomes provided oxidative pressure parameters (measurement of malondialdehyde, or MDA, a primary biomarker for lipid peroxidation), serum degrees of advanced oxidation protein solutions (AOPP), and irritation markers (degrees of C-reactive protein). Added secondary results incorporated alteration of vitamin D stages in excess of time, blood stress, lipid profile, system mass index (BMI), concentrations of complete and ionized calcium, and atherogenic possibility.

A complete of 130 eligible clients were being randomly assigned 1:1 to 1 of 2 groups: 65 patients acquired oral vitamin D3 treatment in addition to their present metformin treatment for a 6-month period, even though the 65 sufferers in the management group continued their metformin therapy with out vitamin D3 supplementation.

Members in the intervention team who were being vitamin D deficient — defined as getting serum levels of 25(OH)D ≤50 nmol/L — took 50,000 IU of vitamin D3 weekly all through the to start with 3 months, followed by 14,000 IU weekly for the duration of the following 3 months. Contributors in the intervention team with 25(OH)D stages >50 nmol/L took 14,000 IU weekly via the conclude of the review.

Baseline scientific and biochemical parameters ended up balanced in between the 2 review groups. Repeated measures 2-way assessment of variance (ANOVA) showed considerable conversation, substantial impact of team, and substantial effect of time.

In the intervention team, serum 25(OH)D levels amplified noticeably through the intervention time period in the management team, these concentrations appreciably amplified for the duration of the initial 3 months then decreased noticeably as a result of month 6. Following 3 and 6 months of vitamin D3 supplementation, 25(OH)D amounts differed considerably involving teams adjustments had been produced for age sexual intercourse and baseline BMI, fasting insulin, and HbA1c.

Considerable consequences of group and time were being pointed out for HbA1c degrees. In the intervention team, HbA1c diminished significantly right after 3 months, adopted by a significant maximize in between months 3 and 6. Just after 3 and 6 months, sizeable concerning-team dissimilarities in HBA1c have been pointed out.

Recurring steps 2-way ANOVA confirmed major results of time for FBG, systolic blood pressure, MDA, whole cholesterol, full calcium whole, and ionized calcium. There was no considerable conversation or outcome of team or time for BMI.

Success of regression analyses showed important concerning-team distinctions in vitamin D at 3 months (B 42.25 95{6654ab549aea683dfb163c18f2e935eca578ab77e61967d7a8b1932c06e74d91} CI, 35.43-49.98 P <.001) and 6 months (B 38.76 95{6654ab549aea683dfb163c18f2e935eca578ab77e61967d7a8b1932c06e74d91} CI, 31.72-45.80 P <.001), as well as a significant mean difference in HbA1c levels at these 2 timepoints (0.20 mmol/L and 0.24 mmol/L, respectively).

Study limitations include the randomized but not placebo controlled nature of the research the use of 25(OH)D but not other forms of vitamin D as markers of vitamin D status the use of HOMA IR to assess insulin resistance rather than the proposed gold standard of hyperinsulinemic-euglycemic clamps and the use of electrochemiluminescence immunoassay for serum 25(OH)D measurement rather than the gold standard method, liquid chromatography mass spectrometry.

“Oral daily doses of vitamin D proposed by [Endocrine Society] guidelines reduce the levels of HbA1c over a 3-month and over a 6-month period,” the investigators wrote. “Its effect on metabolic control, through the improvement on HOMA-IR and oxidative stress measured through AOPP improvement might have a promising effect if vitamin D could be maintained [at an] optimal dose.”

“Further investigation,” they added, “would reconsider vitamin D doses in patients with [T2D], which may attenuate the oxidative stress risk, the risk of metabolic syndrome, and the related cardiovascular events.”


Cojic M, Kocic R, Klisic A, Kocic G. The effects of vitamin D supplementation on metabolic and oxidative stress markers in patients with type 2 diabetes: a  6-month follow-up randomized controlled study. Front Endocrinol. Published online August 19, 2021. doi:10.3389/fendo.2021.610893